Dual-mode dopamine sensor using CsPbBr3-PQD-COF nanocomposites achieves femtosecond sensitivity (0.3 fM fluorescence, 2.5 fM EIS) with visual readout and high specificity for biomedical applications.
3 July 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
The intricate relationship between gut microbiota and the brain has emerged as a pivotal area of research, particularly in understanding myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This complex condition is characterized by debilitating fatigue, cognitive dysfunction, and a wide array of systemic manifestations, posing significant challenges for diagnosis and treatment. Recent studies highlight the microbiota-gut-brain axis as a crucial pathway in ME/CFS pathophysiology, suggesting that alterations in gut microbial composition may impact immune responses, neurochemical signaling, and neuronal health. This narrative review systematically explores English-language scholarly articles from January 1995 to January 2025, utilizing databases such as PubMed, Scopus, and Web of Science. The findings underscore the potential for targeted therapeutic interventions aimed at correcting gut dysbiosis. As research progresses, a deeper understanding of the microbiota-gut-brain connection could lead to innovative approaches for managing ME/CFS, ultimately enhancing the quality of life for affected individuals.
Objective Polypharmacy, the concurrent use of five or more medications, is prevalent among older adults with Diabetes, a population at elevated risk for medication-related complications. Complex treatment regimens for Diabetes and its comorbidities exacerbate challenges such as medication non-adherence, drug interactions, adverse events, and increased hospitalization risk. This review aimed to estimate the prevalence of polypharmacy among older adults with Diabetes. Method Following PRISMA 2020 guidelines, we performed a systematic search of PubMed, Embase, and Web of Science. Screened articles using Nested Knowledge software. Eligible studies included those aged 60 years or older with Diabetes, reporting on the prevalence of polypharmacy. Study quality was assessed using a modified Newcastle-Ottawa Scale, and meta-analysis was performed using random-effects models in R software version 4.4.1. Publication bias was indicated by a Doi plot with an LFK index. Results The pooled prevalence of polypharmacy was 59% (95% CI, 48%-70%). Subgroup analyses showed a prevalence of 55% in retrospective studies and 62% in cross-sectional studies. Sensitivity analyses confirmed the stability of the results. Significant geographic variability was noted, with lower prevalence in high-income countries compared to regions in Southern Europe and Asia. Conclusions Polypharmacy is highly prevalent among older adults with Diabetes, with significant variability across study designs and geographic regions. Targeted interventions and further research are essential to address its associated risks and optimize medication management.